Testosterone and glucose metabolism in men: current concepts and controversies
- PMID: 24353306
- DOI: 10.1530/JOE-13-0393
Testosterone and glucose metabolism in men: current concepts and controversies
Abstract
A wealth of observational studies show that low testosterone is associated with insulin resistance and with an increased risk of diabetes and the metabolic syndrome. Experimental studies have identified potential mechanisms by which low testosterone may lead to insulin resistance. Visceral adipose tissue is an important intermediate in this relationship. Actions of testosterone or its metabolite oestradiol on other tissues such as muscle, liver, bone or the brain, and body composition-independent effects may also play a role. However, definitive evidence from randomised controlled trials (RCTs) to clarify whether the association of low testosterone with disordered glucose metabolism is causative is currently lacking. It therefore remains possible that this association is due to reverse causation, or simply originates by association with common health and lifestyle factors. RCTs of testosterone therapy in men with or without diabetes consistently show modest metabolically favourable changes in body composition. Despite this, testosterone effects on glucose metabolism have been inconsistent. Recent evidence suggests that the hypothalamic-pituitary-testicular axis suppression in the majority of obese men with metabolic disorders is functional, and may be, at least in part, reversible with weight loss. Until further evidence is available, lifestyle measures with emphasis on weight reduction, treatment of comorbidities and optimisation of diabetic control should remain the first-line treatment in these men. Such measures, if successful, may be sufficient to normalise testosterone levels in men with metabolic disorders, who typically have only modest reductions in circulating testosterone levels.
Keywords: diabetes; glucose metabolism; insulin resistance; obesity; testosterone.
Similar articles
-
Low testosterone in men with type 2 diabetes: significance and treatment.J Clin Endocrinol Metab. 2011 Aug;96(8):2341-53. doi: 10.1210/jc.2011-0118. Epub 2011 Jun 6. J Clin Endocrinol Metab. 2011. PMID: 21646372 Review.
-
Testosterone and type 2 diabetes.Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):247-56. doi: 10.1097/MED.0b013e32833919cf. Curr Opin Endocrinol Diabetes Obes. 2010. PMID: 20418720 Review.
-
Late-onset hypogonadism: metabolic impact.Andrology. 2020 Nov;8(6):1519-1529. doi: 10.1111/andr.12705. Epub 2019 Sep 25. Andrology. 2020. PMID: 31502758 Review.
-
Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome.Obes Rev. 2012 Dec;13 Suppl 2:6-13. doi: 10.1111/j.1467-789X.2012.01033.x. Obes Rev. 2012. PMID: 23107255 Review.
-
Androgens and obesity.Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):224-32. doi: 10.1097/MED.0b013e3283398ee2. Curr Opin Endocrinol Diabetes Obes. 2010. PMID: 20418719 Review.
Cited by
-
Male Obesity-related Secondary Hypogonadism - Pathophysiology, Clinical Implications and Management.Eur Endocrinol. 2019 Aug;15(2):83-90. doi: 10.17925/EE.2019.15.2.83. Epub 2019 Aug 16. Eur Endocrinol. 2019. PMID: 31616498 Free PMC article. Review.
-
Association between fasting glucose and all-cause mortality according to sex and age: a prospective cohort study.Sci Rep. 2017 Aug 15;7(1):8194. doi: 10.1038/s41598-017-08498-6. Sci Rep. 2017. PMID: 28811570 Free PMC article.
-
Systemic effects of the hormonal treatment of male hypogonadism with preliminary indications for the management of COVID-19 patients.Ther Adv Endocrinol Metab. 2020 Oct 13;11:2042018820966438. doi: 10.1177/2042018820966438. eCollection 2020. Ther Adv Endocrinol Metab. 2020. PMID: 33133492 Free PMC article. Review.
-
Testosterone Levels and Type 2 Diabetes-No Correlation with Age, Differential Predictive Value in Men and Women.Biomolecules. 2018 Aug 20;8(3):76. doi: 10.3390/biom8030076. Biomolecules. 2018. PMID: 30127326 Free PMC article.
-
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.Adv Ther. 2017 Jun;34(6):1291-1326. doi: 10.1007/s12325-017-0556-1. Epub 2017 May 19. Adv Ther. 2017. PMID: 28526997 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources